Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Autolus Therapeutics (AUTL) Profit After Tax (2017 - 2025)

Autolus Therapeutics' Profit After Tax history spans 6 years, with the latest figure at -$90.3 million for Q4 2025.

  • For Q4 2025, Profit After Tax fell 227.74% year-over-year to -$90.3 million; the TTM value through Dec 2025 reached -$287.5 million, down 30.29%, while the annual FY2025 figure was -$287.5 million, 30.3% down from the prior year.
  • Profit After Tax reached -$90.3 million in Q4 2025 per AUTL's latest filing, down from -$79.1 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of -$26.9 million in Q4 2022 to a low of -$90.3 million in Q4 2025.
  • Average Profit After Tax over 4 years is -$54.1 million, with a median of -$46.8 million recorded in 2023.
  • Peak YoY movement for Profit After Tax: surged 64.28% in 2024, then tumbled 227.74% in 2025.
  • A 4-year view of Profit After Tax shows it stood at -$26.9 million in 2022, then tumbled by 186.47% to -$77.2 million in 2023, then soared by 64.28% to -$27.6 million in 2024, then crashed by 227.74% to -$90.3 million in 2025.
  • Per Business Quant, the three most recent readings for AUTL's Profit After Tax are -$90.3 million (Q4 2025), -$79.1 million (Q3 2025), and -$47.9 million (Q2 2025).